Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HER2-Negative Breast Carcinoma: early-phase trial registry
16 of 19 indexed HER2-Negative Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 16 currently recruiting · #902 of 28,707 conditions by registered trial count
HER2-Negative Breast Carcinoma: 19 US clinical trials tracked, 16 recruiting.
HER2-Negative Breast Carcinoma is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Emory University, running 3 of these trials.
Enrollment posture brief
Registry condition her2-negative-breast-carcinoma
OPEN 16 | RECR 84% | LATE 4 | EARLY 9 | RANK #902 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia Refractory (85% recruiting · 13 trials)
HER2-Negative Breast Carcinoma lists 16 open slots (84% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HER2-Negative Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HER2-Negative Breast Carcinoma is recruiting above its size-band peers.
16 of 19 indexed trials (84.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HER2-Negative Breast Carcinoma research.
Emory University accounts for 3 of 19 trials (15.8%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical HER2-Negative Breast Carcinoma enrolment sits around 58 participants.
Median target enrolment is 58 among the 19 trials that report a genuine target (sentinel values excluded). 10 of those (52.6%) plan for fewer than 100 participants.
-
HER2-Negative Breast Carcinoma research is mostly interventional.
18 interventional and 1 observational studies make up this index (94.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
NCT06058377
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals
NCT07085767
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals
NCT06016738
Mobile Health for Adherence in Breast Cancer Patients
ECOG-ACRIN Cancer Research Group
NCT06112613
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT07483307
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
City of Hope Medical Center
NCT06042569
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
Emory University
NCT06534125
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
University of California, San Francisco
NCT06774027
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Sarah Sammons, MD
NCT06176261
Neoadjuvant Breast Cancer Time Restricted Eating
Thomas Jefferson University
NCT05327608
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Margaret Gatti-Mays
NCT06026657
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05677802
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
Mayo Clinic
NCT06450873
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Emory University
NCT05464810
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy
Emory University
NCT05488145
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06678269
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Alliance for Clinical Trials in Oncology
NCT04379570
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI)
NCT04052555
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
University of Washington
NCT02157051
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on HER2-Negative Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HER2-Negative Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HER2-Negative Breast Carcinoma page
19 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 HER2-Negative Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Emory University sponsors the most HER2-Negative Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See Emory University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HER2-Negative Breast Carcinoma condition card totals 19 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.